Lupin delivers exceptional Q4 results with PAT surging 87.7 percent to ₹1,468.7 crore, nearly doubling profits from ₹782.4 crore a year ago. Consolidated sales climbed 32.9 percent to ₹7,391.9 crore, driven by robust US market performance where sales jumped 56.9 percent to ₹3,398.7 crore. India operations also strengthened with sales rising 11.5 percent to ₹1,908.2 crore. For the full fiscal year 2026, the pharmaceutical major reported consolidated PAT surge of 62 percent to ₹5,355.5 crore against ₹3,306.3 crore previously. Managing Director Nilesh Gupta highlighted the strength across key geographies and outlined plans for strategic investments in technology and operational efficiencies. The board recommended a dividend of ₹18 per equity share, pending shareholder approval at the upcoming annual general meeting.
